However, the frequency of co‐occurring TP53 and KEAP1‐NRF2‐pathway mutations in patients with EGFR‐mutant NSCLC, as well as their impact on the prognosis, remains unknown. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.